Pfizer Share Buyback: What You Need to Know

Pfizer has a long history of share buybacks, dating back to 2011. The company has repurchased over 1 billion shares since then.

In 2020, Pfizer announced a new share buyback program, authorizing the repurchase of up to $10 billion in shares. This was in addition to the $5 billion already allocated for buybacks.

The goal of Pfizer's share buyback program is to return value to shareholders by reducing the number of outstanding shares. This can help increase earnings per share and make the company more attractive to investors.

Pfizer has a history of buying back its own shares, with five successful stock purchase programs completed since 1991, totaling 686 million shares.

The company's board of directors has authorized the repurchase of up to $5 billion worth of its currently-issued stock, with a limit of 120 million shares.

As of May 31, Pfizer had approximately 6.3 billion shares of common stock outstanding, leaving a significant amount of shares available for repurchase.

Pfizer expects the buybacks to be made from time to time during the next 18 months in the open market or in privately-negotiated transactions.

Since 1991, Pfizer has successfully completed five stock purchase programs, demonstrating its confidence in the business and commitment to building shareholder value.

The company's new repurchase program is in addition to approximately $4 billion of authorization remaining under its current repurchase program, increasing the company's total repurchase authorization to $9 billion.

Pfizer currently expects to repurchase approximately $5 billion of its common stock during 2011 with the remaining authorized amount available in 2012 and beyond.

As of December 31, 2010, Pfizer had repurchased approximately 60 million shares under the current repurchase program, showing the company's ongoing commitment to share repurchases.

Pfizer has a long history of paying consistent dividends to its shareholders, with a dividend payout ratio of around 50% over the past decade. This indicates that the company prioritizes returning value to its shareholders through dividends.

In 2020, Pfizer paid a quarterly dividend of $0.38 per share, bringing the annual dividend payment to $1.52 per share. This represents a 6.5% yield based on the company's stock price at the time.

Pfizer's dividend policy is designed to be sustainable and flexible, allowing the company to adjust its dividend payments based on its financial performance. This means that the dividend payout ratio may fluctuate over time.

The company has a strong track record of increasing its dividend payments over the years, with a 10-year dividend growth rate of 5.5%. This demonstrates Pfizer's commitment to returning value to its shareholders through dividends.

As of 2020, Pfizer had paid out over $15 billion in dividends to its shareholders since 2005, highlighting the company's focus on shareholder returns.